Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 3/2017

01.06.2017 | Research Article

The effect of intravenous isosorbide dinitrate in acute decompensated heart failure in hospital

verfasst von: Jérémy Chambord, David Attivi, Véronique Thuus, Claire Zeghmouli, Stéphane Gibaud

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Background According to new recommendations for the management of acute decompensated heart failure (ADHF) in 2015, intravenous vasodilator therapy might be given as an early therapy when systolic blood pressure is normal to high (≥110 mmHg). Only 29% of patients with ADHF are treated with vasodilators without medical contraindication. Objective To evaluate the effect of the systematic use of ISDN on ADHF without contraindication especially on rehospitalization rate. Settings The 600-bed hospital (Centre Hospitalier de l’Ouest Vosgien, Neufchâteau, France). Methods This is a retrospective study with data analysed from medical records. Patients with ADHF episodes and hospitalization in the cardiology department or intensive care unit (ICU) between November 2013 and December 2015 were included resulting in 199 hospitalizations in the analysis (37 were treated by ISDN, and 162 were not). Main outcome measure Effects of ISDN on 180-day hospital readmission for ADHF or acute myocardial infarction (AMI), in-hospital mortality, length of stay, number of ICU admissions, and ICU length of stay. Results Patients who received ISDN required more ICU admissions than the other patients (54.1 vs 33.3%, p = 0.02). Nevertheless 180-day hospital readmission was lower for patients who were receiving ISDN (8.1 vs 22.8%, p = 0.04). ISDN did not influence other clinical outcomes tested. Conclusion ISDN may minimize or prevent the consequences of altered haemodynamics. Lower rehospitalization rate with ISDN was seen in this study.
Literatur
2.
Zurück zum Zitat Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388–442.CrossRefPubMed Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388–442.CrossRefPubMed
3.
Zurück zum Zitat Mebazaa A, Yilmaz MB, Levy P, Ponikowski P, Peacock WF, Laribi S, et al. Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail. 2015;17:544–58.CrossRefPubMed Mebazaa A, Yilmaz MB, Levy P, Ponikowski P, Peacock WF, Laribi S, et al. Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail. 2015;17:544–58.CrossRefPubMed
4.
Zurück zum Zitat Peacock WF, Emerman C, Costanzo MR, Diercks DB, Lopatin M, Fonarow GC. Early vasoactive drugs improve heart failure outcomes. Congest Heart Fail. 2009;15:256–64.CrossRefPubMed Peacock WF, Emerman C, Costanzo MR, Diercks DB, Lopatin M, Fonarow GC. Early vasoactive drugs improve heart failure outcomes. Congest Heart Fail. 2009;15:256–64.CrossRefPubMed
5.
Zurück zum Zitat Lemachatti N, Philippon AL, Bloom B, Hausfater P, Riou B, Ray P, et al. Temporal trends in nitrate utilization for acute heart failure in elderly emergency patients: a single-centre observational study. Arch Cardiovasc Dis. 2016;109:449–56.CrossRefPubMed Lemachatti N, Philippon AL, Bloom B, Hausfater P, Riou B, Ray P, et al. Temporal trends in nitrate utilization for acute heart failure in elderly emergency patients: a single-centre observational study. Arch Cardiovasc Dis. 2016;109:449–56.CrossRefPubMed
6.
Zurück zum Zitat Ho EC, Parker JD, Austin PC, Tu JV, Wang X, Lee DS. Impact of nitrate use on survival in acute heart failure: a propensity-matched analysis. J Am Heart Assoc. 2016;. doi:10.1161/JAHA.115.002531. Ho EC, Parker JD, Austin PC, Tu JV, Wang X, Lee DS. Impact of nitrate use on survival in acute heart failure: a propensity-matched analysis. J Am Heart Assoc. 2016;. doi:10.​1161/​JAHA.​115.​002531.
7.
Zurück zum Zitat Beohar N, Erdogan AK, Lee DC, Sabbah HN, Kern MJ, Teerlink J, et al. Acute heart failure syndromes and coronary perfusion. J Am Coll Cardiol. 2008;52:13–6.CrossRefPubMed Beohar N, Erdogan AK, Lee DC, Sabbah HN, Kern MJ, Teerlink J, et al. Acute heart failure syndromes and coronary perfusion. J Am Coll Cardiol. 2008;52:13–6.CrossRefPubMed
8.
Zurück zum Zitat Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO. Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol. 2013;61:391–403.CrossRefPubMed Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO. Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol. 2013;61:391–403.CrossRefPubMed
9.
Zurück zum Zitat Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341:577–85.CrossRefPubMed Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341:577–85.CrossRefPubMed
10.
Zurück zum Zitat Gheorghiade M, De Luca L, Fonarow GC, Filippatos G, Metra M, Francis GS. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol. 2005;96:11G–7G.CrossRefPubMed Gheorghiade M, De Luca L, Fonarow GC, Filippatos G, Metra M, Francis GS. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol. 2005;96:11G–7G.CrossRefPubMed
11.
Zurück zum Zitat Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation. 2003;108:833–8.CrossRefPubMed Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation. 2003;108:833–8.CrossRefPubMed
12.
Zurück zum Zitat McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14:803–69.CrossRefPubMed McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14:803–69.CrossRefPubMed
13.
Zurück zum Zitat Abrams J. Beneficial actions of nitrates in cardiovascular disease. Am J Cardiol. 1996;77:31C–7C.CrossRefPubMed Abrams J. Beneficial actions of nitrates in cardiovascular disease. Am J Cardiol. 1996;77:31C–7C.CrossRefPubMed
14.
Zurück zum Zitat Risordan 10 mg/10 ml injectable. In: Le Dictionnaire Vidal. Paris (France): Editions Vidal, 2016. p. 2369–2370. Risordan 10 mg/10 ml injectable. In: Le Dictionnaire Vidal. Paris (France): Editions Vidal, 2016. p. 2369–2370.
15.
Zurück zum Zitat Butler J, Forman DE, Abraham WT, Gottlieb SS, Loh E, Massie BM, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J. 2004;147:331–8.CrossRefPubMed Butler J, Forman DE, Abraham WT, Gottlieb SS, Loh E, Massie BM, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J. 2004;147:331–8.CrossRefPubMed
Metadaten
Titel
The effect of intravenous isosorbide dinitrate in acute decompensated heart failure in hospital
verfasst von
Jérémy Chambord
David Attivi
Véronique Thuus
Claire Zeghmouli
Stéphane Gibaud
Publikationsdatum
01.06.2017
Verlag
Springer International Publishing
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 3/2017
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-017-0459-x

Weitere Artikel der Ausgabe 3/2017

International Journal of Clinical Pharmacy 3/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.